cyrilzakka/clinical-trials huggingface dataset:
Association Between Embryo Implantation Rate and Maternal Age

To explore the relationship between maternal age and embryo implantation rate in patients undergoing assisted reproductive technology.

The investigators designed a retrospective clinical trial conducted from January 2015 to December 2020 at the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School. Infertility was defined as the failure of a clinical pregnancy after 12 months or more of regular unprotected intercourse with the same marriage partner. Patients experiencing infertility no younger than the age of 20 who attended the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School for the first time and had experienced no less than one embryo transplantation between January 2015 and December 2019 were recruited. Patients who had experienced or canceled embryo transplantation cycles for any reason were excluded from this study. The gap year from December 2019 to December 2020 allowed researchers to follow up on the outcomes of pregnancies before 2020. Frozen cycles were performed when high-quality embryos existed to avoid unnecessary ovarian stimulation and oocyte retrieval processes. Investigators were blinded to the outcome of embryo transplantation, and information on pregnancy was gathered through telephone follow-up one year after transplantation.

Eligibility Criteria:
Inclusion Criteria:

1. infertile patients
2. attended the Reproductive Medicine Center of the Affiliated Drum Tower Hospital of Nanjing University Medical School for the first time
3. had experienced no less than one embryo transplantation between January 2015 and December 2019

Exclusion Criteria:

canceled embryo transplantation cycles for any reason
Get Ready And Empowered About Treatment

The purpose of this study is to rigorously assess a program designed to empower patient living with HIV, to improve their health care and health, and to reduce disparities.

Our project has four major aims:

1. Assess improvement in patient empowerment
2. Assess improvement in patients' receipt of evidence-based care
3. Assess improvement in patients' health
4. Assess reduction in disparities in empowerment

Eligibility Criteria:
Inclusion Criteria:

* age18 years or older,
* confirmed HIV diagnosis
* receipt of care within a participating site.

Exclusion Criteria:

* inability to provide informed consent
* limited English proficiency (Trainings and Personal Health Record are currently only available in English)
Taurine as a Possible Anti-aging Therapy?

Among the strategies that can improve the body's ability to counteract oxidative stress, the use of nutritional antioxidants has been investigated. Taurine is a "semi-essential" amino acid, also called a nitrogen compound, which has been used as an effective antioxidant due to its ability to neutralize hypochlorous acid, an extremely toxic oxidant produced by leukocytes in the inflammatory process in humans.

Objective: To evaluate the oxidative parameters of women aged 55 to 70 years after 16 weeks of taurine supplementation.

Methods: Twenty-four women age 55 to 70 will be randomly assigned to two groups: control group (GC), supplemented with placebo (1.5 g of starch); and taurine group (GTAU), supplemented with taurine (1.5 g), for 16 weeks. Anthropometry, functional capacity test, taurine, and levels of oxidative stress markers will be determined in pre and post intervention plasma samples. Food consumption will be assessed before, during, and after the intervention. The results will be analyzed by an ANOVA two-way repeated measures mixed model, with the Sidak post hoc (p \< 0.05).

Eligibility Criteria:
Inclusion Criteria:

* Had being aged 55-70 years;
* Female;
* Post-menopausal;
* Sedentary (not practicing physical exercise for at least 6 months).

Exclusion Criteria:

* Chronic kidney diseases;
* Infectious contagious diseases;
* Coronary heart disease;
* Smokers
* Alcoholics.
Diagnostic Value of C-reactive Protein for Detection of Postoperative Inflammatory Complications After Gastroesophageal Cancer Surgery

Although widely used, there is a lack of evidence concerning diagnostic value of C-reactive protein (CRP) in the postoperative course. The aim of this study was to evaluate the diagnostic accuracy of CRP for postoperative inflammatory complications after gastroesophageal cancer.


Eligibility Criteria:
Inclusion Criteria:

* all patients with gastroesophageal cancer surgery

Exclusion Criteria:

* lack of measurement of C-reactive protein
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days

The purpose of this study is to investigate the effect of 3 different regimens of subcutaneous (SC) administered hCRF (1.0 mg every \[Q\] 8 hours \[h\], 1.5 mg Q12h, and 1.0 mg Q12h) on the reduction of PBE in patients with primary malignant or metastatic brain tumors as defined by MRI indexes.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older.
* Written informed consent has been provided and documented.
* Primary malignant or metastatic brain tumor that is either asymptomatic or symptomatic patients with the life expectancy estimation of 3 months or more
* A pretreatment MRI brain scan must identify at least 1 dominant tumor lesion and related PBE that is radiologically (or visibly) distinct from the main tumor mass; the combined tumor-edema lesion must be \> 2 cm in longest diameter (for at least 1 slice) and visible in 3 consecutive, 4 mm sections on MRI.
* No dexamethasone or anti-angiogenic treatment for at least 14 days prior to the Baseline and throughout the study.
* A Karnofsky Performance Score \> 60 at Screening (Visit 1) and at Baseline
* A negative serum pregnancy test at the Screening (Visit 1) is required for women of childbearing potential.

Exclusion Criteria:

* • Low-grade gliomas, recurrent gliomas, suspected lymphoma, or known human immunosuppressive virus (HIV) infection.

  * Patients requiring surgery, radiosurgery or radiation surgery therapy
  * Patients experiencing severe symptoms related to PBE
  * Patients where MRI is contraindicated for any reason.
  * Signs and/or symptoms of relatively severe cerebral herniation.
  * Concurrent enrollment in any other investigational drug or device study, or plan to enroll in such a study during the 3 to 4 weeks of study treatment.
  * Systemic corticosteroid use (with the exception of inhalers for asthma).
  * Use of dexamethasone (eg, as an anti-emetic) during screening or during the study
  * Use of anti-angiogenic/anti-vascular endothelial growth factor (VEGF) therapy or anticonvulsant therapy (if patient's liver function tests (LFTs) are \> 3 times upper limit of normal) 14 days prior to randomization
  * Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal, or endocrine metabolic disease, which in the opinion of the Investigator or the Medical Monitor, would put the patient as unusual risk during study participation.
  * Known renal insufficiency or screening glomerular filtration rate (GFR) \< 60 mL/min/1.73 m2.
  * Central nervous system infection, human immunosuppressive virus (HIV) positive or ongoing infectious process.
  * For female patients: pregnancy, breastfeeding or refusal to practice birth control if of childbearing potential during the study.
  * Inability of the patient to follow the treatment regimen.
  * Known history of methionine allergy.
Post-Stroke Medication Relay

Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects).

Improvements in the use of medications in the community and in hospital follow-up.

Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients managed in stroke unit following ischemic stroke
* Benefiting from a direct return home
* Non-opposition to participation

Exclusion Criteria:

- None
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder

In an earlier phase of this study, a cognitive behavioral therapy (CBT) manual to treat body dysmorphic disorder (BDD) symptoms was developed. We are currently implementing this manual-based treatment to validate its effectiveness in patients with BDD.

BDD is a disease that involves preoccupation with imagined or minor physical flaws. The condition often begins in adolescence and, if left untreated, can cause significant social, emotional, and occupational distress. Within the last decade, BDD has received increased attention, and various modes of treatment have been utilized and evaluated. CBT has been found to be a more effective form of treatment than other types of psychotherapy. In this study, we have created a new CBT treatment manual and are currently implementing it to evaluate its effectiveness in patients with BDD. The utility of this manual for different populations will also be evaluated, and adherence and competence measures to assess CBT delivery will be developed.

This study will last 24 weeks. Participants will be randomly assigned (like the flip of a coin) to either start CBT treatment immediately or to a waitlist group, which would require a 3-month wait without treatment before beginning treatment for this study. Participants have a 50-50 chance of being in either group. Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques. Self-report scales will be used to assess participants.

Eligibility Criteria:
Inclusion Criteria:

* DSM-IV diagnosis of BDD for at least 6 months prior to study entry
* Score higher than 23 on BDD Yale-Brown Obsessive Compulsive Scale
* Live within driving distance of Boston, MA or Providence, RI

Exclusion Criteria:

* Any psychiatric diagnoses other than BDD
* Alcohol abuse or dependence within 3 months prior to study entry
* Suicidal or homicidal
* Psychotropic medication within 2 months prior to study entry
Antimicrobial Activity of Two Mouthwashes

This is a three arm randomized trial. The aim is to evaluate the antimicrobial activity of chlorhexidine and polyhexamethylene biguanide oral antiseptics on the microorganisms of the oral cavity. A total of 30 healthy volunteers will be enrolled and randomly allocated to control group (CG, n=10), which will be instructed to rinse the mouth with 10ml of a sterile saline solution for one minute, to chlorhexidine group (ClG, n=10), which will be instructed to rinse the mouth with 10ml of an 0.12% chlorhexidine solution, for one minute, or to polyhexamethylene biguanide group (PG, n=10), which will be instructed to rinse the mouth with 10ml of an 0.07% polyhexamethylene biguanide solution, for one minute. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes. Samples will be plated on manitol agar, mitis salivarius agar, EMB agar and Sabouraud agar. Samples will be processed by a blinded microbiologist.


Eligibility Criteria:
Inclusion Criteria:

* patients aged 18-30 years

Exclusion Criteria:

* patients with a hypersensitivity or allergic response by some component of the formula antiseptics,
* pregnant women,
* lactating,
* history of periodontal disease,
* smoking,
* decompensated diabetics,
* patients undergoing chemotherapy,
* radiotherapy patient,
* transplanted patient and refuses to participate,
* not signing a term of free and informed concentiment
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) with Advanced Prostate Cancer (CaP)

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with advanced prostate cancer.

PRIMARY OBJECTIVES:

I. To evaluate a highly innovative project evaluating the feasibility of patient-centered home care PCHC as a new model of cancer care to reduce disparities and improve health related QoL (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). (Phase I) II. Establish patient-centeredness by exploring patients' choice relative to the place of CaP treatment for certain aspects of therapy as well as end-of-life care.

III. Establish the acceptance and impact of PCHC on PROs and HRQoL in BM with advanced CaP.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP 1: Participants take part in a focus group or complete questionnaires and may take part in an interview on study.

GROUP 2: Participants complete questionnaires throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* GROUP 1 FOCUS GROUPS:

  * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer

GROUP 1 SURVEYS:

* Are 18 years of age or older
* Have histologic evidence of prostate adenocarcinoma
* Are requiring prostate cancer therapy
* Have an understanding of the protocol and its requirements
* Are willing to fill in a questionnaire and participate in a focused interview
* Are able and willing to sign an informed consent

GROUP 1 INTERVIEWS:

* Enrollment in the survey phase of the protocol

GROUP 2:

* Are 18 years of age or older
* Have histologic evidence of prostate adenocarcinoma
* Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
* Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of advanced care at home program (ACH)
* Have an understanding of the protocol and its requirements
* Are able and willing to sign an informed consent

Exclusion Criteria:

* GROUP 1 FOCUS GROUPS:

  * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system

GROUP 1 SURVEYS:

* Do not identify as Black men
* Have not been diagnosed with advanced/metastatic CaP
* Are not requiring active standard anti-cancer therapy

GROUP 1 INTERVIEWS:

* Not enrolled in the survey phase of the protocol

GROUP 2:

* Do not identify as Black men
* Have not been diagnosed with advanced/metastatic CaP
* Are not requiring active standard anti-cancer therapy
Effects of Exercise Training in Survivors of Lymphoma

This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

In this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. Therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. Participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. This study recruits through invitation only.

The primary endpoint in this study is the change in cardiorespiratory fitness, assessed as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.

Eligibility Criteria:
Inclusion Criteria Lymphoma participants:

* Listed in relevant registers
* Confirmed lymphoma diagnosis (i.e., Hodgkin lymphoma and aggressive non-Hodgkin lymphoma)
* Completed treatment in the past two to five years without relapse or second cancer
* Previous anthracycline treatment with or without mediastinal radiation
* No severe cancer-related fatigue (per self-report)

Inclusion Criteria Lymphoma participants and non-cancer reference group:

* Currently not performing \>75 minutes/week of aerobic exercise
* Willing and able to adhere to all study procedures.

Exclusion Criteria Lymphoma participants:

* Relapse since diagnosis
* A history, or current presence, of another diagnosis of invasive cancer of any kind

Exclusion Criteria Lymphoma participants and non-cancer reference group:

* Presence of any uncontrolled- or recent cardiovascular disease
* Has undergone heart surgery
* Uses a pacemaker
* Pregnancy
* Unable to read and understand Swedish (applicable for the Swedish site only)
* Unable to read and understand Norwegian (applicable for the Norwegian site)
* Any physical or mental health condition restricting adherence to study protocol
Minimal and Brief Treatments for Pathological Gamblers

The purpose of the study is to examine whether problem gamblers who receive therapy calls in addition to a self-help manual will be more likely to quit or cut back on their gambling when compared with problem gamblers who receive just the manual.

With gambling becoming more accessible, the occurrence of problems related to gambling are on the rise. The costs of problem gambling are enormous.There are social and economic costs, the gambler can sometimes lose a significant relationship, job, or commit an illegal activity. Pathological gamblers are also at risk for developing a general medical condition related to stress. There is a high risk of suicide and problem gamblers also have increased rates of mental health disorders. Relatively few people choose to attend formal treatment programs so it's important to provide a range of options to make treatment more accessible. The present study examines the effectiveness of minimal and brief interventions delivered by the telephone.

Comparison(s): The "Workbook Only Control" condition involves receiving the self-help booklet through the mail after a brief telephone assessment. The "Minimal Treatment" condition involves receiving the same workbook but also having a motivational enhancement intervention by telephone. The "Brief Treatment" condition provides the workbook, motivational enhancement, and follow-up support on six occasions spread over 36 weeks. The "Wait List Control" condition involves participants being assigned to a six week waiting list. Participants are assessed and after a six week waiting period they will have a reassessment at which time they will be sent the gambling self-help workbook.

Eligibility Criteria:
Inclusion Criteria:

* Over age 17
* Perception of a gambling problem and a score of 3 or higher (moderate risk) on the Canadian Problem Gambling Index.
* Not involved in treatment at present.
* Willingness to read a short book written in English as a major treatment.
* Willing to have telephone contacts recorded.
* Willing to provide follow-up data on gambling.
* Willing to provide the name of a collateral to help locate them for follow-up interviews.
* Must have gambled at least once in the past month

Exclusion Criteria:

* Participants in the preliminary study will be excluded.
Effectiveness of "Medisinstart"

"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.

The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.


Eligibility Criteria:
Inclusion Criteria:

First time prescription for a drug belonging to one of the following groups (ATC-code):

* Dabigatran etexilate (B01AE07)
* Rivaroxaban (B01AF01)
* Apixaban (B01AF02)
* Beta blocking agents (C07)
* Calcium channel blockers (C08)
* Agents acting on the renin-angiotensin system (C09)
* HMG CoA reductase inhibitors (statins) (C10AA)

Exclusion Criteria:

* Prior use (within the last 3 years) of the drug in question independent of strength, dose and formulation
Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers

Sugar alcohols such as xylitol and erythritol are increasingly popular as sugar substitutes in the food industry and are also recommended to diabetic patients. Both substances are already in use in the food industry and are freely available. Since the 1970s, beneficial effects on oral health could be demonstrated as oral bacteria were influenced positively. A pilot study recently undertaken in the US (Flint N, 2014) has shown that diabetics profit from a daily intake of erythritol, as this natural sweetener enhances the elasticity of the blood vessels. In this trial, investigators aim to examine whether this effect can be found in a non-diabetic but obese cohort, and whether also xylitol improves vascular function.


Eligibility Criteria:
Inclusion Criteria:

* Obese volunteers (BMI \> 30kg/m2)
* Aged 18- max. 55 years
* Otherwise healthy.

Exclusion Criteria:

* Known cardiovascular disease
* Diabetes mellitus
* Smoking and drug abuse
* Arterial hypertension with antihypertensive treatment
* Dyslipidaemia with statin therapy
* Known chronic hepatic disease (NASH, hepatitis).
* Known renal disease: kidney failure
* Pregnancy
* Chronical diseases of the gastrointestinal tract, history of gastrointestinal surgery with major changes to the gastrointestinal tract
* Substance abuse, alcohol abuse.
* Inability to follow procedures due to psychological disorders, dementia or insufficient knowledge of project language (German).
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.


Eligibility Criteria:
Inclusion Criteria:

* Visual Analogue Scale (VAS) of pain is higher than 40 mm.
* Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

Exclusion Criteria:

* Malignancy within the past 2 years.
* Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
* Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).
* Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.
* Skin conditions in the affected dermatome that could alter sensation.